ProfileGDS5678 / 1426302_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 38% 38% 38% 37% 39% 40% 39% 37% 38% 37% 38% 39% 39% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9007938
GSM967853U87-EV human glioblastoma xenograft - Control 22.8719438
GSM967854U87-EV human glioblastoma xenograft - Control 32.8616838
GSM967855U87-EV human glioblastoma xenograft - Control 42.7869537
GSM967856U87-EV human glioblastoma xenograft - Control 52.8467639
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0189940
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9498239
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8358337
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8526538
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8211837
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.852938
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8560739
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8902539
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8593738